Dr. Dean is Director of New Alliances at the International AIDS Vaccine Initiative (IAVI), where she leads technology identification efforts geared toward addressing unmet needs in a portfolio of international collaborative HIV vaccine research and development projects. Prior to joining IAVI, Dr. Dean was Director of Program Management with PowderJect Vaccines, Inc., managing a portfolio of preclinical and clinical projects in the areas of prophylactic and therapeutic vaccines for infectious diseases, cancer and allergy. Previously, Dr. Dean headed the Viral Vaccine Development group at Schering-Plough Animal Health. Dr. Dean received a Ph.D. in Microbiology and Immunology from Northwestern University Medical School, where she studied molecular virology, and a B.S. in Chemistry from the University of Michigan.
Blogged on behalf of Milana Shapira and Sophia Doll
Dr Hanzi Dean from IAVI further stressed the need for PPPs by drawing instances from the effort to develop an HIV vaccine. The magnitude of the task demands that partnerships be set up, making this a key focus of IAVI’s mission. IAVI has formed R&D partnership; regional partnerships, such as with the Uganda Ministry of Health; and global advocacy and outreach programmes. What was clear was that it’s core mission is to ensure development a preventative HIV vaccine. Thanks to partnerships, global engagement, sustained political support and fundamental research, translation and clinical development can be continued.
The presentations from the event will be made available from the 1st November.
For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation